コンテンツへスキップ
Merck
  • Can tonsillectomy modify the innate and adaptive immunity pathways involved in IgA nephropathy?

Can tonsillectomy modify the innate and adaptive immunity pathways involved in IgA nephropathy?

Journal of nephrology (2014-04-24)
Luca Vergano, Elisa Loiacono, Roberto Albera, Rosanna Coppo, Roberta Camilla, Licia Peruzzi, Alessandro Amore, Maria Elena Donadio, Federica Chiale, Alberto Boido, Filippo Mariano, Gianna Mazzucco, Sara Ravera, Giovanni Cancarini, Riccardo Magistroni, Giulietta Beltrame, Cristiana Rollino, Piero Stratta, Marco Quaglia, Roberto Bergia, Raffaella Cravero, Stefano Cusinato, Luisa Benozzi, Silvana Savoldi, Carola Licata
要旨

The benefits of tonsillectomy in IgA nephropathy (IgAN) are still debated. Tonsillectomy may remove pathogen sources and reduce the mucosal associated lymphoid tissue (MALT), limiting degalactosylated IgA1 (deGal-IgA1) production, which is considered to be the initiating pathogenetic event leading to IgA glomerular deposition. In the European network VALIGA, 62/1147 IgAN patients underwent tonsillectomy (TxIgAN). In a cross-sectional study 15 of these patients were tested and compared to 45 non-tonsillectomized IgAN (no-TxIgAN) and healthy controls (HC) regarding levels of deGal-IgA1, and markers of innate immunity and oxidative stress, including toll-like receptors (TLR)2, 3, 4 and 9 mRNAs, proteasome (PS) and immunoproteasome (iPS) mRNAs in peripheral blood mononuclear cells (PBMC), and advanced oxidation protein products (AOPP). Levels of deGal-IgA1 were lower in TxIgAN than in no-TxIgAN (p = 0.015), but higher than in HC (p = 0.003). TLR mRNAs were more expressed in TxIgAN than in HC (TLR4, p = 0.021; TLR9, p = 0.027), and higher in TxIgAN than in no-TxIgAN (p ≤ 0.001 for TLR2, 4, 9). A switch from PS to iPS was detected in PBMC of TxIgAN in comparison to HC and it was higher than in no-TxIgAN [large multifunctional peptidase (LMP)2/β1, p = 0.039; LPM7/β5, p < 0.0001]. The levels of AOPP were significantly higher in TxIgAN than HC (p < 0.001) and no-TxIgAN (p = 0.033). In conclusion, the activation of innate immunity via TLRs and ubiquitin-proteasome pathways and the pro-oxidative milieu were not affected by tonsillectomy, even though the levels of aberrantly galactosylated IgA1 were lower in patients with IgAN who had tonsillectomy. The residual hyperactivation of innate immunity in tonsillectomized patients may result from extra-tonsillar MALT.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ヨウ化カリウム, ACS reagent, ≥99.0%
Sigma-Aldrich
ヨウ化カリウム, ReagentPlus®, 99%
Sigma-Aldrich
塩化マグネシウム, anhydrous, ≥98%
Sigma-Aldrich
塩化マグネシウム 溶液, for molecular biology, 1.00 M±0.01 M
Sigma-Aldrich
ヨウ化カリウム, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99%
Sigma-Aldrich
ホスファターゼの基質, 5 mg tablets
Sigma-Aldrich
ラウリン酸, ≥98%, FCC, FG
Sigma-Aldrich
4-ニトロフェニルリン酸 二ナトリウム塩 六水和物, suitable for enzyme immunoassay, ≥99.0% (enzymatic)
Sigma-Aldrich
塩化マグネシウム, powder, <200 μm
Sigma-Aldrich
塩化マグネシウム 溶液, BioUltra, for molecular biology, 2 M in H2O
Sigma-Aldrich
ヨウ化カリウム, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, 99%
Sigma-Aldrich
塩化マグネシウム, BioReagent, suitable for insect cell culture, ≥97.0%
Sigma-Aldrich
4-ニトロフェニルリン酸 二ナトリウム塩 六水和物, tablet
Sigma-Aldrich
ヨウ化カリウム, puriss., meets analytical specification of Ph. Eur. BP, USP, 99.0-100.5% (calc. to the dried substance)
Sigma-Aldrich
4-ニトロフェニルリン酸 二ナトリウム塩 六水和物, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
ホスファターゼの基質, powder
Sigma-Aldrich
4-ニトロフェニルリン酸 二ナトリウム塩 六水和物, tablet
Sigma-Aldrich
ヨウ化カリウム, ≥99.99% trace metals basis
Sigma-Aldrich
ドデカン酸, 98%
Sigma-Aldrich
ラウリン酸, natural, ≥98%, FCC, FG
Sigma-Aldrich
塩化マグネシウム 溶液, PCR Reagent, 25 mM MgCI2 solution for PCR
Sigma-Aldrich
ヨウ化カリウム, BioUltra, ≥99.5% (AT)
Sigma-Aldrich
塩化マグネシウム, AnhydroBeads, −10 mesh, 99.9% trace metals basis
Sigma-Aldrich
塩化マグネシウム 溶液, BioUltra, for molecular biology, ~1 M in H2O
Sigma-Aldrich
ヨウ化カリウム, JIS special grade, ≥99.5%
Sigma-Aldrich
ホスファターゼの基質, 40 mg tablets
Sigma-Aldrich
ヨウ化カリウム, suitable for plant cell culture
Sigma-Aldrich
4-ニトロフェニルリン酸 二ナトリウム塩 六水和物, tablet
Sigma-Aldrich
ドデカン酸, ≥99% (GC/titration)
Supelco
ヨウ化カリウム, Pharmaceutical Secondary Standard; Certified Reference Material